You are here: Industry Insights > Atlas

News List

Atlas Antibodies acquires HistoCyte Laboratories, a global leader in cell line controls for histopathology prnasia
February 20, 2021
Atlas Antibodies AB has signed an agreement to acquire UK company HistoCyte Laboratories Ltd. HistoCyte Laboratories' portfolio of innovative cell line materials provides control of immunohistochemical assays used in the diagnosis of cancers.
Triplet Therapeutics launches to focus on Huntington’s disease drugs pharmaceutical-technology
December 19, 2019
Biotechnology company Triplet Therapeutics has launched to develop treatments for more than 40 triplet repeat disorders, including Huntington’s disease.
Genocea’s GEN-009 Vaccine Achieves Positive Results contractpharma
June 19, 2019
Post-vaccination T cell responses detected to 91% of vaccine neoantigens, including CD8+ T cell responses to 53% of vaccine neoantigens.
Encouraging data for ViiV’s long-acting, two-drug HIV therapy pharmatimes
November 01, 2018
ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV...
ViiV, Janssen’s two-drug HIV regimen hits PhIII targets pharmatimes
August 16, 2018
ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.
Atlas awarded £2m grant for infectious disease test pharmatimes
August 16, 2017
Atlas Genetics has been awarded a £2 million grant by Innovate UK for a project that aims to support the adoption of its io rapid diagnostic platform into UK sexual health clinics.